Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.
Insulin Biosimilar MarketThe global insulin biosimilar market is on track for significant expansion, with an estimated valuation of approximately USD 3,008.0 million in 2024. Exhibiting a year-on-year ...